About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
- 2014 Rate Card & Production Specs
- 2013 Rate Card & Production Specs
- Advertising Due Dates
- BPA Statement
Statement of Purpose
Guidelines for Authors
Evaluation of Discharge Medication Orders Following Automatic Therapeutic Substitution of Commonly Exchanged Drug Classes
In a retrospective chart review of adult patients admitted to an academic medical center, 15% of the 317 patients identified as being subject to automatic therapeutic substitution for one of five drug classes were not returned to original outpatient therapy upon discharge, and 16% were receiving a cost-prohibitive drug.
Sarah Glaholt, PharmD; Genevieve L. Hayes, PharmD, BCPS; and Christopher S. Wisniewski, PharmD, BCPS
Federal and State Decisions Will Have a Big Impact on Pharmacists
Unlike a generic drug, a “generic” biologic won’t be identical to the branded product. Manufacturers are divided over whether pharmacists should have to tell doctors when they prescribe one of the “biosimilars” that will soon appear on the market.
Although Progress Has Been Slow, a Renowned Expert on the Disease Sees Reasons for Hope
The prognosis for patients with pancreatic cancer remains poor, but a widely recognized expert on pancreatic and biliary surgery at Massachusetts General Hospital and Harvard Medical School expresses optimism about improvements in the next decade.
Many hypertension patients want to learn about ways to reduce reliance on pharmaceuticals, says functional medicine practitioner Mark Houston, who believes it is often possible to reduce or eliminate reliance on drugs using nutrition and nutraceuticals.
Matthew Grissinger, RPh, FaScP
Office of Pharmacy Affairs Promises Regulatory Response
FDA approvals, drug indications, and updates
Ibrutinib (Imbruvica) for chronic lymphocytic leukemia, tasimelteon (Hetlioz) for non-24-hour sleep–wake disorder, and anti-inhibitor coagulant complex (Feiba) to prevent or reduce bleeding in hemophilia A or B
Marvin M. Goldenberg, PhD, RPh, MS
Tiffany Bennett, David Bray, and Michael W. Neville, PharmD, BCPS, FASHP